Current Price Disclosure cycle – 2026 October
The 2026 October cycle has a data collection period of 1 October 2025 to 31 March 2026.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 May 2026.
The reduction day is 1 October 2026.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health, Disability and Ageing. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations have been published in the National Health (Weighted average disclosed price – October 2026 reduction day) Determination 2026 on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their June 2026 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2026 will also take the reduction on 1 October 2026 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute is 13 July 2026.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices (WADPs) is presented in the table below.
|
Legal Instrument Drug |
Legal Instrument Form |
Legal Instrument MoA |
Brands of PI designated brands under 99ADHC (Y/N) |
Floor Price |
Average Unadjusted Price Reduction (UPR) at least 12.5% over 3 consecutive cycles (Y/N) |
April 2026 |
October 2026 |
UPR (%) |
Threshold |
Calculations based on: |
|
Abiraterone |
Tablet containing abiraterone acetate 250 mg |
Oral |
N |
0 |
- |
775.46 |
565.55 |
27.07% |
10% |
OWAPD |
|
Abiraterone |
Tablet containing abiraterone acetate 500 mg |
Oral |
N |
0 |
- |
775.46 |
565.55 |
27.07% |
10% |
OWAPD |
|
Adalimumab |
Injection 40 mg in 0.4 mL pre-filled pen |
Injection |
N |
0 |
- |
444.17 |
392.56 |
11.62% |
10% |
GWAPD |
|
Adalimumab |
Injection 40 mg in 0.8 mL pre-filled pen |
Injection |
N |
0 |
- |
444.17 |
392.56 |
11.62% |
10% |
GWAPD |
|
Adalimumab |
Injection 40 mg in 0.8 mL pre-filled syringe |
Injection |
N |
0 |
- |
444.17 |
392.56 |
11.62% |
10% |
GWAPD |
|
Adalimumab |
Injection 80 mg in 0.8 mL pre-filled pen |
Injection |
N |
0 |
- |
618.9 |
546.98 |
11.62% |
10% |
GWAPD |
|
Atomoxetine |
Capsule 10 mg (as hydrochloride) |
Oral |
Y |
28.68 |
Y |
28.68 |
25.04 |
12.69% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 18 mg (as hydrochloride) |
Oral |
Y |
28.68 |
Y |
28.68 |
25.04 |
12.69% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 25 mg (as hydrochloride) |
Oral |
Y |
28.68 |
Y |
28.68 |
25.04 |
12.69% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 40 mg (as hydrochloride) |
Oral |
Y |
28.68 |
Y |
28.68 |
25.04 |
12.69% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 60 mg (as hydrochloride) |
Oral |
Y |
28.68 |
Y |
28.68 |
25.04 |
12.69% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 80 mg (as hydrochloride) |
Oral |
Y |
37.29 |
Y |
37.29 |
32.56 |
12.68% |
10% |
OWAPD |
|
Atovaquone |
Oral suspension 750 mg per 5 mL, 210 mL |
Oral |
N |
0 |
- |
670.15 |
568.21 |
15.21% |
10% |
OWAPD |
|
Azathioprine |
Tablet 25 mg |
Oral |
Y |
7.8 |
Y |
7.8 |
6.87 |
11.92% |
10% |
GWAPD |
|
Azathioprine |
Tablet 50 mg |
Oral |
Y |
13.29 |
Y |
13.29 |
11.7 |
11.96% |
10% |
GWAPD |
|
Bendamustine |
Powder for injection containing bendamustine hydrochloride 100 mg |
Injection |
N |
0 |
- |
58.49 |
42.69 |
27.01% |
10% |
OWAPD |
|
Bendamustine |
Powder for injection containing bendamustine hydrochloride 25 mg |
Injection |
N |
0 |
- |
14.62 |
10.67 |
27.02% |
10% |
OWAPD |
|
Bivalirudin |
Powder for I.V. injection 250 mg (as trifluoroacetate) |
Injection |
Y |
413.89 |
N |
413.89 |
280.37 |
32.26% |
30% |
OWAPD |
|
Buprenorphine |
Transdermal patch 10 mg |
Transdermal |
Y |
12.62 |
Y |
12.62 |
10.99 |
12.92% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 15 mg |
Transdermal |
Y |
16.04 |
Y |
16.04 |
13.97 |
12.91% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 20 mg |
Transdermal |
Y |
19.47 |
Y |
19.47 |
16.95 |
12.94% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 25 mg |
Transdermal |
Y |
22.71 |
Y |
22.71 |
19.77 |
12.95% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 30 mg |
Transdermal |
Y |
25.95 |
Y |
25.95 |
22.59 |
12.95% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 40 mg |
Transdermal |
Y |
32.45 |
Y |
32.45 |
28.25 |
12.94% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 5 mg |
Transdermal |
Y |
7.01 |
Y |
7.01 |
6.1 |
12.98% |
10% |
GWAPD |
|
Cabergoline |
Tablet 1 mg |
Oral |
N |
0 |
- |
24.82 |
21.64 |
12.81% |
10% |
GWAPD |
|
Cabergoline |
Tablet 500 micrograms |
Oral |
N |
0 |
- |
9.1 |
7.93 |
12.86% |
10% |
GWAPD |
|
Carbimazole |
Tablet 5 mg |
Oral |
N |
0 |
- |
6.25 |
5.43 |
13.12% |
10% |
GWAPD |
|
Ceftriaxone |
Powder for injection 1 g (as sodium) |
Injection |
Y |
25.5 |
Y |
25.5 |
19.72 |
22.67% |
10% |
OWAPD |
|
Ceftriaxone |
Powder for injection 2 g (as sodium) |
Injection |
Y |
12.85 |
Y |
12.85 |
9.94 |
22.65% |
10% |
OWAPD |
|
Cefuroxime |
Tablet 250 mg (as axetil) |
Oral |
Y |
5.27 |
Y |
5.27 |
4.31 |
18.22% |
10% |
GWAPD |
|
Dabigatran etexilate |
Capsule 75 mg (as mesilate) |
Oral |
N |
0 |
- |
8.5 |
6.88 |
19.06% |
10% |
OWAPD |
|
Darunavir |
Tablet 600 mg |
Oral |
N |
0 |
- |
577.86 |
396.06 |
31.46% |
10% |
OWAPD |
|
Darunavir |
Tablet 600 mg (as ethanolate) |
Oral |
N |
0 |
- |
662.53 |
396.06 |
40.22% |
10% |
OWAPD |
|
Darunavir |
Tablet 800 mg |
Oral |
N |
0 |
- |
385.23 |
264.04 |
31.46% |
10% |
OWAPD |
|
Darunavir |
Tablet 800 mg (as ethanolate) |
Oral |
N |
0 |
- |
385.23 |
264.04 |
31.46% |
10% |
OWAPD |
|
Dasatinib |
Tablet 100 mg |
Oral |
Y |
365.62 |
Y |
365.62 |
252.46 |
30.95% |
30% |
GWAPD |
|
Dasatinib |
Tablet 20 mg |
Oral |
Y |
221.98 |
Y |
221.98 |
153.28 |
30.95% |
30% |
GWAPD |
|
Dasatinib |
Tablet 50 mg |
Oral |
Y |
365.62 |
Y |
365.62 |
252.46 |
30.95% |
30% |
GWAPD |
|
Dasatinib |
Tablet 70 mg |
Oral |
Y |
452.66 |
Y |
452.66 |
312.56 |
30.95% |
30% |
GWAPD |
|
Deferasirox |
Tablet 180 mg |
Oral |
Y |
29.02 |
Y |
29.02 |
18.32 |
36.87% |
30% |
GWAPD |
|
Deferasirox |
Tablet 360 mg |
Oral |
Y |
58.04 |
Y |
58.04 |
36.63 |
36.89% |
30% |
GWAPD |
|
Deferasirox |
Tablet 90 mg |
Oral |
Y |
14.51 |
Y |
14.51 |
9.16 |
36.87% |
30% |
GWAPD |
|
Denosumab |
Injection 120 mg in 1.7 mL |
Injection |
N |
0 |
- |
296.93 |
254.64 |
14.24% |
10% |
OWAPD |
|
Denosumab |
Injection 60 mg in 1 mL pre-filled syringe |
Injection |
N |
0 |
- |
159.38 |
136.69 |
14.24% |
10% |
OWAPD |
|
Desvenlafaxine |
Tablet (extended release) 100 mg (as succinate) |
Oral |
Y |
7.92 |
Y |
7.92 |
7.02 |
11.36% |
10% |
OWAPD |
|
Desvenlafaxine |
Tablet (modified release) 100 mg |
Oral |
Y |
7.92 |
Y |
7.92 |
7.02 |
11.36% |
10% |
OWAPD |
|
Desvenlafaxine |
Tablet (modified release) 100 mg (as benzoate) |
Oral |
Y |
7.92 |
Y |
7.92 |
7.02 |
11.36% |
10% |
OWAPD |
|
Desvenlafaxine |
Tablet (modified release) 50 mg |
Oral |
Y |
6.45 |
Y |
6.45 |
5.72 |
11.32% |
10% |
OWAPD |
|
Desvenlafaxine |
Tablet (modified release) 50 mg (as benzoate) |
Oral |
Y |
6.45 |
Y |
6.45 |
5.72 |
11.32% |
10% |
OWAPD |
|
Dimethyl fumarate |
Capsule (modified release) 240 mg |
Oral |
N |
0 |
- |
300.62 |
242.03 |
19.49% |
10% |
GWAPD |
|
Fingolimod
|
Capsule 500 micrograms (as hydrochloride) |
Oral |
N |
0 |
- |
695.7 |
401.84 |
42.24% |
10% |
GWAPD |
|
Fulvestrant |
Injection 250 mg in 5 mL pre-filled syringe |
Injection |
N |
0 |
- |
134.6 |
113.82 |
15.44% |
10% |
GWAPD |
|
Ganciclovir |
Powder for I.V. infusion 500 mg (as sodium) |
Injection |
Y |
116.09 |
Y |
116.09 |
98.42 |
15.22% |
10% |
OWAPD |
|
Ganirelix |
Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe |
Injection |
N |
0 |
- |
18.53 |
16.55 |
10.69% |
10% |
GWAPD |
|
Hydromorphone |
Injection containing hydromorphone hydrochloride 10 mg in 1 mL |
Injection |
Y |
7.52 |
Y |
7.52 |
6.06 |
19.41% |
10% |
OWAPD |
|
Hydromorphone |
Injection containing hydromorphone hydrochloride 2 mg in 1 mL |
Injection |
Y |
5.64 |
Y |
5.64 |
4.55 |
19.33% |
10% |
OWAPD |
|
Hyoscine |
Injection containing hyoscine butylbromide 20 mg in 1 mL |
Injection |
Y |
6.57 |
Y |
6.57 |
5.58 |
15.07% |
10% |
GWAPD |
|
Icatibant |
Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe |
Injection |
N |
0 |
- |
420.88 |
328.62 |
21.92% |
10% |
OWAPD |
|
Infliximab |
Powder for I.V. infusion 100 mg |
Injection |
Y |
186.16 |
Y |
186.16 |
158.2 |
15.02% |
10% |
GWAPD |
|
Infliximab |
Solution for injection 120 mg in 1 mL pre-filled pen |
Injection |
Y |
252.4 |
Y |
252.4 |
214.49 |
15.02% |
10% |
GWAPD |
|
Irinotecan |
I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL |
Injection |
Y |
11.35 |
Y |
11.35 |
8.08 |
28.81% |
10% |
OWAPD |
|
Irinotecan |
I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL |
Injection |
Y |
56.75 |
Y |
56.75 |
40.4 |
28.81% |
10% |
OWAPD |
|
Lacosamide |
Tablet 100 mg |
Oral |
N |
0 |
- |
11.42 |
9.73 |
14.80% |
10% |
GWAPD |
|
Lacosamide |
Tablet 150 mg |
Oral |
N |
0 |
- |
17.12 |
14.59 |
14.78% |
10% |
GWAPD |
|
Lacosamide |
Tablet 200 mg |
Oral |
N |
0 |
- |
91.3 |
77.79 |
14.80% |
10% |
GWAPD |
|
Lacosamide |
Tablet 50 mg |
Oral |
N |
0 |
- |
5.7 |
4.86 |
14.74% |
10% |
GWAPD |
|
Latanoprost with timolol |
Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
Application to the eye |
Y |
7.58 |
Y |
7.58 |
5.96 |
21.37% |
10% |
GWAPD |
|
Lenalidomide |
Capsule 10 mg |
Oral |
N |
0 |
- |
325.55 |
176.28 |
45.85% |
10% |
GWAPD |
|
Lenalidomide |
Capsule 15 mg |
Oral |
N |
0 |
- |
392.09 |
212.31 |
45.85% |
10% |
GWAPD |
|
Lenalidomide |
Capsule 20 mg |
Oral |
N |
0 |
- |
505.16 |
222.22 |
56.01% |
10% |
GWAPD |
|
Lenalidomide |
Capsule 25 mg |
Oral |
N |
0 |
- |
512.99 |
277.77 |
45.85% |
10% |
GWAPD |
|
Lenalidomide |
Capsule 5 mg |
Oral |
N |
0 |
- |
248.5 |
134.56 |
45.85% |
10% |
GWAPD |
|
Levothyroxine |
Tablet containing 100 micrograms anhydrous levothyroxine sodium |
Oral |
N |
0 |
- |
8.32 |
7.38 |
11.30% |
10% |
GWAPD |
|
Levothyroxine |
Tablet containing 125 micrograms anhydrous levothyroxine sodium |
Oral |
N |
0 |
- |
10.68 |
9.47 |
11.33% |
10% |
GWAPD |
|
Levothyroxine |
Tablet containing 200 micrograms anhydrous levothyroxine sodium |
Oral |
N |
0 |
- |
9.76 |
8.65 |
11.37% |
10% |
GWAPD |
|
Levothyroxine |
Tablet containing 50 micrograms anhydrous levothyroxine sodium |
Oral |
N |
0 |
- |
8.03 |
7.12 |
11.33% |
10% |
GWAPD |
|
Levothyroxine |
Tablet containing 75 micrograms anhydrous levothyroxine sodium |
Oral |
N |
0 |
- |
8.17 |
7.24 |
11.38% |
10% |
GWAPD |
|
Methotrexate |
Tablet 10 mg |
Oral |
N |
0 |
- |
7.5 |
6.71 |
10.53% |
10% |
OWAPD |
|
Methotrexate |
Tablet 2.5 mg |
Oral |
N |
0 |
- |
5.42 |
4.85 |
10.52% |
10% |
OWAPD |
|
Mycophenolic acid |
Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid |
Oral |
Y |
85.79 |
Y |
85.79 |
70.91 |
17.34% |
10% |
GWAPD |
|
Olanzapine |
Tablet 10 mg |
Oral |
Y |
6.34 |
Y |
6.34 |
5.61 |
11.51% |
10% |
GWAPD |
|
Olanzapine |
Tablet 10 mg (orally disintegrating) |
Oral |
Y |
6.34 |
Y |
6.34 |
5.61 |
11.51% |
10% |
GWAPD |
|
Olanzapine |
Tablet 15 mg (orally disintegrating) |
Oral |
Y |
9.52 |
Y |
9.52 |
8.42 |
11.55% |
10% |
GWAPD |
|
Olanzapine |
Tablet 20 mg (orally disintegrating) |
Oral |
Y |
12.69 |
Y |
12.69 |
11.22 |
11.58% |
10% |
GWAPD |
|
Olanzapine |
Tablet 7.5 mg |
Oral |
Y |
4.76 |
Y |
4.76 |
4.21 |
11.55% |
10% |
GWAPD |
|
Olmesartan with amlodipine |
Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) |
Oral |
Y |
5.56 |
Y |
5.56 |
4.82 |
13.31% |
10% |
GWAPD |
|
Olmesartan with amlodipine |
Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) |
Oral |
Y |
5.18 |
Y |
5.18 |
4.5 |
13.13% |
10% |
GWAPD |
|
Paclitaxel, nanoparticle albumin-bound |
Powder for I.V. injection containing 100 mg paclitaxel |
Injection |
N |
0 |
- |
217.82 |
172.25 |
20.92% |
10% |
OWAPD |
|
Pirfenidone |
Tablet 267 mg |
Oral |
N |
0 |
- |
123.41 |
102.53 |
16.92% |
10% |
OWAPD |
|
Pirfenidone |
Tablet 801 mg |
Oral |
N |
0 |
- |
370.24 |
307.6 |
16.92% |
10% |
OWAPD |
|
Plerixafor |
Injection 24 mg in 1.2 mL |
Injection |
N |
0 |
- |
1129.54 |
799.38 |
29.23% |
10% |
GWAPD |
|
Posaconazole |
Tablet (modified release) 100 mg |
Oral |
Y |
104.77 |
Y |
104.77 |
78.45 |
25.12% |
10% |
OWAPD |
|
Rivaroxaban |
Capsule 15 mg |
Oral |
N |
0 |
- |
26.99 |
16.05 |
40.53% |
10% |
OWAPD |
|
Rivaroxaban |
Capsule 20 mg |
Oral |
N |
0 |
- |
26.66 |
15.85 |
40.55% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 10 mg |
Oral |
N |
0 |
- |
11.39 |
9.11 |
20.02% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 15 mg |
Oral |
N |
0 |
- |
20.05 |
16.05 |
19.95% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 2.5 mg |
Oral |
N |
0 |
- |
20.11 |
16.09 |
19.99% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 20 mg |
Oral |
N |
0 |
- |
19.81 |
15.85 |
19.99% |
10% |
OWAPD |
|
Sitagliptin with metformin |
Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride |
Oral |
N |
0 |
- |
29.48 |
23.09 |
21.68% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride |
Oral |
N |
0 |
- |
30.47 |
23.86 |
21.69% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride |
Oral |
N |
0 |
- |
21.31 |
16.69 |
21.68% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride |
Oral |
N |
0 |
- |
20.33 |
15.92 |
21.69% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride |
Oral |
N |
0 |
- |
21.01 |
16.46 |
21.66% |
10% |
GWAPD |
|
Tacrolimus |
Capsule 0.5 mg (once daily prolonged release) |
Oral |
Y |
37.52 |
Y |
37.52 |
31.67 |
15.59% |
10% |
GWAPD |
|
Temozolomide |
Capsule 5 mg |
Oral |
Y |
4.74 |
Y |
4.74 |
4 |
17.30% |
10% |
GWAPD |
|
Terbinafine |
Tablet 250 mg (as hydrochloride) |
Oral |
Y |
11.88 |
Y |
11.88 |
10.35 |
12.88% |
10% |
GWAPD |
|
Ticagrelor |
Tablet 90 mg |
Oral |
N |
0 |
- |
81.59 |
72.36 |
11.31% |
10% |
OWAPD |
|
Valganciclovir |
Tablet 450 mg (as hydrochloride) |
Oral |
Y |
238.11 |
Y |
238.11 |
195.35 |
17.96% |
10% |
OWAPD |
|
Vancomycin |
Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) |
Injection |
Y |
6 |
Y |
6 |
4.95 |
17.50% |
10% |
OWAPD |
|
Varenicline |
Box containing 11 tablets 0.5 mg and 42 tablets 1 mg |
Oral |
N |
0 |
- |
45.35 |
31.92 |
29.61% |
10% |
OWAPD |
|
Varenicline |
Tablet 1 mg |
Oral |
N |
0 |
- |
53.46 |
37.63 |
29.61% |
10% |
OWAPD |
Flow-on price disclosure reductions
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction in accordance with the National Health Act 1953 on 1 October 2026 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-OCT-2026 (Excel 11.9KB). Sponsors are able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial discretion.
Indicative prices of brands scheduled for a price disclosure reduction
The indicative prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices reports will be published in July 2026.
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex‑manufacturer prices (AEMPs) for brands scheduled to take a price disclosure reduction. The reports for the 2026 October cycle will be published in September 2026.
Brand price reductions and savings to patients
The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 October 2026. This information is made available to assist patients understand how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report for the 2026 October cycle will be published in September 2026.